Building on previous research that revealed varying concentrations of WNT5A in LUAD and LUSC in tumour tissue the present study sought to investigate WNT5A levels bound to exosomes and in blood serum samples devoid of EVs including exosomes, to reveal the role of WNT5A as a potential biomarker for clinical applications including disease progression, therapy response and patient survival [16, 24]. Here, WNT5A is linked to neoplasm.